Patents by Inventor Karl Richard Gibson

Karl Richard Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100240652
    Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
    Type: Application
    Filed: January 15, 2007
    Publication date: September 23, 2010
    Inventors: Karl Richard Gibson, Melanie Susanne Glossop
  • Patent number: 7572797
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: August 11, 2009
    Assignee: Pfizer Inc.
    Inventors: Stephen Mark Denton, Karl Richard Gibson, Melanie Susanne Glossop, Mark Ian Kemp, Cedric Poinsard
  • Publication number: 20090048306
    Abstract: The present invention relates to compounds of the formula (I): and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
    Type: Application
    Filed: May 2, 2008
    Publication date: February 19, 2009
    Applicant: Pfizer, Inc.
    Inventors: Sharanjeet Kaur Bagal, Karl Richard Gibson, Mark Ian Kemp, Cedric Poinsard, Blanda Luzia Christa Stammen, Stephen Martin Denton, Melanie Susanne Glossop
  • Patent number: 7410964
    Abstract: Compounds of formula I: inhibit gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: August 12, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Kevin Dinnell, Karl Richard Gibson, Timothy Harrison, Richard Alexander Jelley, Alan John Nadin, Paul Joseph Oakley, Andrew Pate Owens, Duncan Edward Shaw, Brian John Williams
  • Publication number: 20080096950
    Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, are useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
    Type: Application
    Filed: October 3, 2007
    Publication date: April 24, 2008
    Inventors: Karl Richard Gibson, Sarah Elizabeth Skerratt, Kevin Neil Dack
  • Patent number: 6337331
    Abstract: Substituted or 6,7-ring fused 1,2,3-triazolo[1,5-&agr;]-pyrimidine derivatives are selective ligands for GABAA receptors useful in the treatment of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: January 8, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Howard Barff Broughton, Jose Luis Castro Pineiro, Ian James Collins, Karl Richard Gibson, Michael Rowley, Leslie Joseph Street
  • Publication number: 20010053776
    Abstract: 9-(4-Methylthiazol-2-yl)- 11-(pyridin-4-yl)-6,7-dihydro-5H-2, 7a-diazadibenzo[a,c]cyclohepten-8-one, and pharmaceutically acceptable salts thereof, are selective ligands for GABAA receptors, in particular having high affinity for the a2 and/or a3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Application
    Filed: May 18, 2001
    Publication date: December 20, 2001
    Inventors: James Michael Crawforth, Karl Richard Gibson, Michael Rowley